As of Mar 27
| +0.30 / +0.43%|
The 32 analysts offering 12-month price forecasts for AstraZeneca have a median target of 70.40, with a high estimate of 88.67 and a low estimate of 54.58. The median estimate represents a +0.48% increase from the last price of 70.07.
The current consensus among 33 polled investment analysts is to Hold stock in AstraZeneca. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.